A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2554 participants.
Also called NCT06268873
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 2,554 participants
- Sponsor
- Registry
-
NCT06268873 -
2023-506457-38-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Malaysia, Netherlands, Peru, Philippines, Poland, Romania, Saudi Arabia, Serbia, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, Ukraine, United Kingdom, Vietnam
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06268873. Randomized; quadruple masking; primary purpose treatment. Start 2024-03-29 (actual); primary completion 2028-02-24 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
- Condition
- Chronic Kidney Disease and Hypertension
- Intervention (Drug)
- Baxdrostat/dapagliflozin
- Intervention (Drug)
- Dapagliflozin in combination with placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06268873- Content hash
205a5bfe82bce6b102cfcefe916da6b23e1a895b0384cf0f1dfff9086c15f89a